Institutional investors purchased a net $1.4 million shares of RGEN during the quarter ended March 2016 and now own 89.77% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
COLUMBIA WANGER ASSET MANAGEMENT... Bought 604.6 Thousand shares of Repligen Corp